Myelofibrosis: Symptom Burden, Risk Stratification and Novel Treatments – Live

Description

Program Description

---

Click to Go to the Event Registration

Myelofibrosis (MF) is a myeloproliferative neoplasm (MPN) characterized by clonal hematopoietic cell expansion with bone marrow fibrosis. MF has the worst prognosis of the classic Philadelphia chromosome negative MPNs. Although the most frequent cause of death is hematologic transformation and disease progression, patients with MF are at high risk for other competing causes of morbidity and mortality. The considerable heterogeneity of MF translates into a wide range of outcomes. Given this heterogeneity, risk stratification for individualized management becomes essential in disease treatment.

Agenda

---

• Overview of pathophysiology, symptom burden, risk stratification, and eligibility for different treatment options for myelofibrosis (MF)
  Rami Komrokji, MD
• Discuss NCCN treatment guidelines-based treatment options, and physician patient communication in the management of MF
  Raajit K. Rampal, MD, PhD

Intended Audience

---

Hematologists/oncologists, nurses, and advanced practice providers (physician assistants, nurse practitioners) caring for patients with MF

Commercial Supporter

---

Supported by an educational grant from CTI Biopharma Corp., a Sobi company.